See more : Dee Tech S.A. (DEE.PA) Income Statement Analysis – Financial Results
Complete financial analysis of BioPorto A/S (THOXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPorto A/S, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Kingwell Group Limited (1195.HK) Income Statement Analysis – Financial Results
- Yongsheng Advanced Materials Company Limited (3608.HK) Income Statement Analysis – Financial Results
- Gold and GemStone Mining Inc. (GGSM) Income Statement Analysis – Financial Results
- Kerry TJ Logistics Company Limited (2608.TW) Income Statement Analysis – Financial Results
- Indoco Remedies Limited (INDOCO.BO) Income Statement Analysis – Financial Results
BioPorto A/S (THOXF)
About BioPorto A/S
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.96M | 28.97M | 24.25M | 23.20M | 26.62M | 26.02M | 25.16M | 20.72M | 20.38M | 18.71M | 16.63M | 17.86M | 18.58M | 13.80M | 11.01M | 8.34M | 8.34M | 5.55M | 4.36M |
| Cost of Revenue | 10.78M | 9.93M | 9.21M | 9.87M | 9.29M | 8.18M | 6.91M | 5.03M | 4.90M | 5.51M | 7.58M | 6.80M | 8.06M | 5.34M | 4.75M | 4.62M | 4.62M | 2.42M | 4.49M |
| Gross Profit | 20.18M | 19.04M | 15.04M | 13.34M | 17.33M | 17.84M | 18.25M | 15.69M | 15.48M | 13.20M | 9.04M | 11.06M | 10.52M | 8.46M | 6.26M | 3.72M | 3.72M | 3.13M | -123.00K |
| Gross Profit Ratio | 65.19% | 65.73% | 62.01% | 57.49% | 65.09% | 68.55% | 72.54% | 75.74% | 75.95% | 70.55% | 54.39% | 61.91% | 56.61% | 61.28% | 56.85% | 44.58% | 44.58% | 56.43% | -2.82% |
| Research & Development | 25.45M | 34.94M | 30.26M | 28.13M | 24.56M | 18.68M | 21.93M | 9.67M | 9.94M | 8.62M | 10.21M | 9.91M | 8.13M | 8.90M | 8.64M | 6.38M | 6.38M | 7.64M | 6.68M |
| General & Administrative | 36.03M | 41.83M | 32.66M | 28.02M | 27.80M | 20.01M | 14.27M | 13.03M | 9.42M | 10.44M | 12.67M | 9.04M | 8.79M | 8.26M | 7.97M | 7.48M | 7.48M | 7.89M | 5.32M |
| Selling & Marketing | 18.87M | 21.22M | 17.38M | 20.79M | 39.27M | 20.94M | 18.55M | 18.04M | 8.88M | 9.40M | 5.97M | 5.97M | 6.46M | 4.71M | 5.67M | 3.90M | 3.90M | 2.26M | 2.23M |
| SG&A | 54.90M | 63.05M | 50.04M | 48.80M | 67.07M | 40.94M | 32.81M | 31.07M | 18.30M | 19.84M | 18.63M | 15.01M | 15.25M | 12.97M | 13.63M | 11.38M | 11.38M | 10.15M | 7.55M |
| Other Expenses | 1.01M | 274.00K | -548.00K | -474.00K | -591.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.35M | 97.99M | 80.30M | 76.93M | 91.63M | 59.62M | 54.74M | 40.74M | 28.24M | 28.45M | 28.85M | 24.92M | 23.38M | 21.87M | 22.28M | 17.76M | 16.78M | -11.53M | -14.48M |
| Cost & Expenses | 92.13M | 107.91M | 89.51M | 86.79M | 100.92M | 67.80M | 61.65M | 45.77M | 33.14M | 33.96M | 36.43M | 31.73M | 31.44M | 27.21M | 27.03M | 22.39M | 21.40M | -9.11M | -9.99M |
| Interest Income | 1.04M | 44.00K | 0.00 | 4.00K | 75.00K | 27.00K | 25.00K | 64.00K | 93.00K | 210.00K | 56.00K | -273.00K | 68.00K | 93.00K | 124.00K | 1.75M | 763.00K | 1.26M | 755.00K |
| Interest Expense | 571.00K | 1.09M | 912.00K | 780.00K | 326.00K | 38.00K | 31.00K | 29.00K | 279.00K | 15.00K | 1.68M | 1.82M | 2.05M | 889.00K | 61.00K | 125.00K | 982.00K | 190.00K | 153.00K |
| Depreciation & Amortization | 2.68M | 3.97M | 4.33M | 3.99M | 2.86M | 543.00K | 504.00K | 390.00K | 300.00K | 270.00K | 107.00K | 189.00K | 8.00K | 325.00K | 345.00K | 384.00K | 395.00K | 442.00K | 460.00K |
| EBITDA | -57.96M | -77.81M | -58.60M | -62.06M | -71.06M | -41.04M | -36.53M | -24.48M | -12.44M | -14.81M | -20.09M | -13.94M | -12.88M | -12.99M | -15.55M | -14.23M | -12.67M | -12.96M | 15.57M |
| EBITDA Ratio | -187.21% | -255.13% | -241.61% | -267.45% | -266.94% | -157.73% | -145.22% | -118.15% | -61.01% | -79.18% | -120.85% | -78.08% | -68.78% | -94.14% | -141.24% | -163.80% | -151.89% | 294.54% | 356.95% |
| Operating Income | -61.17M | -77.88M | -65.26M | -63.59M | -74.30M | -41.78M | -36.49M | -25.05M | -12.76M | -15.26M | -19.80M | -13.87M | -12.86M | -13.41M | -16.02M | -14.05M | -14.05M | 14.66M | 14.36M |
| Operating Income Ratio | -197.60% | -268.83% | -269.05% | -274.05% | -279.09% | -160.60% | -145.08% | -120.88% | -62.60% | -81.56% | -119.11% | -77.67% | -69.19% | -97.17% | -145.50% | -168.41% | -168.41% | 263.94% | 329.09% |
| Total Other Income/Expenses | -35.00K | -2.60M | 1.42M | -3.24M | 52.00K | 164.00K | -570.00K | 148.00K | -255.00K | 159.00K | -2.07M | -2.08M | -1.98M | -796.00K | 63.00K | -697.00K | -219.00K | 30.39M | 602.00K |
| Income Before Tax | -61.21M | -81.55M | -63.84M | -66.83M | -74.25M | -41.62M | -37.06M | -24.90M | -13.01M | -15.10M | -21.87M | -15.95M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | 15.73M | 14.96M |
| Income Before Tax Ratio | -197.71% | -281.50% | -263.21% | -288.03% | -278.89% | -159.97% | -147.34% | -120.17% | -63.85% | -80.71% | -131.57% | -89.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | 283.17% | 342.89% |
| Income Tax Expense | -4.88M | -5.62M | -6.73M | -5.27M | -4.61M | -3.57M | -4.82M | -2.10M | -2.28M | -2.17M | -1.25M | -1.25M | 68.00K | 93.00K | 124.00K | 0.00 | 982.00K | 32.71M | 30.67M |
| Net Income | -56.33M | -75.92M | -57.11M | -61.56M | -69.64M | -38.05M | -32.24M | -22.80M | -10.73M | -12.93M | -20.62M | -14.70M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | -15.73M | -14.96M |
| Net Income Ratio | -181.95% | -262.08% | -235.48% | -265.31% | -261.60% | -146.25% | -128.18% | -110.04% | -52.65% | -69.10% | -124.05% | -82.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | -283.17% | -342.89% |
| EPS | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| EPS Diluted | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| Weighted Avg Shares Out | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
| Weighted Avg Shares Out (Dil) | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting
August 7, 2024 News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, August 7, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company...
BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms
July 30, 2024 News Release BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms ADLM 2024 Conference – Chicago, July 30, 2024 – BioPorto Diagnostics, a pioneering company in...
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
July 29, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 29, 2024 – BioPorto Diagnostics, a company specializing in in vitro diagnostics with an emphasis...
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company specializing in in vitro diagnostics with an emphasis...
BioPorto confirms market acceptance of NGAL products with US standing order.
July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused...
Changes of number of shares and votes in BioPorto A/S
June 24, 2024 Announcement no. 15 Changes of number of shares and votes in BioPorto A/S.
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
June 18, 2024 Announcement no. 14 Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
June 17, 2024 Announcement no. 13 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION...
BioPorto A/S Appoints Chief Financial Officer
May 30, 2024 Announcement no. 12 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Niels Høy Nielsen as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive...
BioPorto A/S Appoints President and CEO of BioPorto Inc.
May 7, 2024 News release BioPorto A/S Appoints President and CEO of BioPorto Inc. COPENHAGEN, DENMARK and BOSTON, MA, USA, May 7, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the...
Source: https://incomestatements.info
Category: Stock Reports